An Automatic Platform Based on Nanostructured Microfluidic Chip for Isolating and Identification of Circulating Tumor...

Area of Science:

• Biomedical Engineering
• Oncology
• Microfluidics

Background:

• Circulating tumor cell (CTC) testing is a vital biomarker in cancer treatment.
• Current CTC detection methods suffer from poor reproducibility and limited sensitivity, hindering clinical application.
• A reliable, automated CTC detection system is crucial for advancing cancer diagnostics.

Purpose of the Study:

• To design and validate a novel automated microfluidic chip-based system for CTC detection.
• To assess the system's reliability and sensitivity using ovarian cancer cell lines and clinical specimens.
• To evaluate the potential of this automated platform as a biomarker for epithelial ovarian cancer (EOC).

Main Methods:

• Development of an automated microfluidic chip system for CTC capture.
• Testing system reliability with SKOV3 ovarian cancer cell line.
• Validation using peripheral blood from healthy volunteers, benign ovarian tumor patients, and EOC patients.
• Utilizing anti-EpCAM and anti-N-cadherin antibodies for enhanced CTC capture.

Main Results:

• The automated system demonstrated high capture rates for SKOV3 cells, reaching 89.6% with dual antibody use.
• The system showed sensitivity to low cell counts and a linear response within the tested range.
• For EOC detection, the CTC test achieved 62.5% sensitivity and 100% specificity.

Conclusions:

• The developed automated microfluidic chip platform offers a high capture rate for CTCs.
• This novel system is feasible and effective for detecting CTCs in epithelial ovarian cancer (EOC).
• The automated CTC detection platform shows promise for improving cancer diagnostics and treatment monitoring.